Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals, Inc. develops and commercializes medicines for hereditary angioedema and other rare diseases. Its commercial product ORLADEYO® (berotralstat) is an oral, once-daily plasma kallikrein inhibitor for HAE, and company updates commonly report ORLADEYO revenue, commercial execution, and financial results.
BioCryst news also covers pipeline and portfolio developments, including investigational plasma kallikrein inhibitor navenibart, rare-disease research programs, licensing arrangements, acquisitions, senior R&D leadership changes, investor conference activity, and Nasdaq inducement equity grants tied to new employee hiring.
BioCryst Pharmaceuticals (BCRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:45 a.m. ET. The event will be conducted virtually, allowing investors to listen via a live audio webcast. BioCryst focuses on developing novel, oral medicines for rare diseases, with products like ORLADEYO® and RAPIVAB® already approved in various regions. The company is also advancing programs for several treatments targeting specific diseases. For more details, visit www.biocryst.com.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement options for 84,000 shares to 11 new employees on November 30, 2021. The options, priced at $12.06 per share, match the stock's closing price on that date and vest over four years. This grant complies with Nasdaq Listing Rule 5635(c)(4). BioCryst focuses on developing oral medicines for rare diseases, with ongoing programs like BCX9930 and BCX9250. Their product ORLADEYO® is already approved in multiple regions, including the U.S. and Europe.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced the enrollment of the first patient in the REDEEM-2 pivotal trial for its oral Factor D inhibitor, BCX9930, aimed at treating paroxysmal nocturnal hemoglobinuria (PNH). This randomized, placebo-controlled trial will involve around 57 patients, with part 1 assessing the drug's safety and efficacy over 12 weeks. Prior trials showed BCX9930 significantly increased hemoglobin levels and was well tolerated. The FDA has granted Fast Track status and Orphan Drug Designation for BCX9930.
BioCryst Pharmaceuticals (BCRX) has secured $350 million in funding through agreements with Royalty Pharma and OMERS Capital Markets. This funding will strengthen the development of BCX9930, an oral Factor D inhibitor, and support the global launch of ORLADEYO® (berotralstat). Royalty Pharma will provide $150 million for royalties on net sales of BCX9930 and ORLADEYO, while OMERS will also contribute $150 million, focusing on royalties from ORLADEYO. This strategic financing aims to advance ongoing pivotal trials and prepare for regulatory submissions, enhancing BioCryst's growth potential.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in several upcoming virtual investor conferences. Notable events include the 2021 Jefferies London Healthcare Conference on November 18, the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, the Evercore ISI HeathCONx Conference on December 1, and the JMP Securities Hematology and Oncology Summit on December 6. Links to live audio webcasts and replays will be available on BioCryst's website. The company focuses on developing innovative medicines for rare diseases.
BioCryst Pharmaceuticals announced promising long-term efficacy and safety data for ORLADEYO (berotralstat) at the 2021 ACAAI Annual Scientific Meeting. The APeX-S study revealed patients switching from injectable prophylactic therapies experienced over 80% attack-free months. ORLADEYO demonstrated low attack rates, with a median of 0.0 attacks per month over 12 months. Patient satisfaction improved significantly, with marked increases in treatment convenience. These results position ORLADEYO as a transformative option for hereditary angioedema (HAE) patients.
BioCryst Pharmaceuticals (BCRX) reported Q3 2021 revenue of $41.0 million, up from $6.1 million year-over-year, driven by ORLADEYO® (berotralstat) net revenue of $37.0 million. The company projects full-year 2021 ORLADEYO revenue between $115 million and $120 million. Strong patient demand persists, with significant physician adoption and near-complete payer coverage. However, R&D expense rose to $50.0 million, and the net loss was $58.8 million, or $0.33 per share. Cash and investments were $203.9 million as of September 30, 2021.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement options for 95,500 shares to 10 new employees as of October 29, 2021. The exercise price is set at $14.93, aligning with the closing stock price on the grant date. The options vest in four annual installments, contingent on continued employment, and have a term of 10 years. BioCryst is focused on developing innovative treatments for rare diseases, with notable products including ORLADEYO® and RAPIVAB®.
BioCryst Pharmaceuticals (Nasdaq:BCRX) has appointed Jinky Ang Rosselli as chief data and insights officer. In this capacity, she will lead a global team to enhance the company’s data science and analytics capabilities, aiming to inform strategic decisions. Rosselli, previously vice president of global business analysis, has a strong background in data-driven insights, which has contributed to the successful launch of ORLADEYO® (berotralstat). Her leadership is expected to further optimize BioCryst's commercial infrastructure and drive future innovations across various disease-related pipelines.
BioCryst Pharmaceuticals (BCRX) will present four abstracts, including a Distinguished Industry Oral Abstract, at the American College of Allergy, Asthma & Immunology (ACAAI) meeting from November 4-8, 2021, in New Orleans. The presentations will focus on ORLADEYO® (berotralstat) for hereditary angioedema (HAE) treatment. Key findings include low HAE attack rates in patients and high patient satisfaction when switching from injectables to ORLADEYO. The company continues to support the transition to oral prophylactic treatments for HAE.